<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<style type="text/css">
.txt { white-space:nowrap; }
#f0 { font-family:sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff0; src: url("0.ttf"); }
#f1 { font-family:ff0,sans-serif; font-weight:bold; font-style:normal; }
@font-face { font-family: ff1; src: url("1.ttf"); }
#f2 { font-family:ff1,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff2; src: url("2.ttf"); }
#f3 { font-family:ff2,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff3; src: url("3.ttf"); }
#f4 { font-family:ff3,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff4; src: url("4.ttf"); }
#f5 { font-family:ff4,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff5; src: url("5.ttf"); }
#f6 { font-family:ff5,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff6; src: url("6.ttf"); }
#f7 { font-family:ff6,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff7; src: url("7.ttf"); }
#f8 { font-family:ff7,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff8; src: url("8.ttf"); }
#f9 { font-family:ff8,serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff9; src: url("9.ttf"); }
#f10 { font-family:ff9,monospace; font-weight:bold; font-style:normal; }
@font-face { font-family: ff10; src: url("10.ttf"); }
#f11 { font-family:ff10,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff11; src: url("11.ttf"); }
#f12 { font-family:ff11,sans-serif; font-weight:normal; font-style:normal; }
</style>
</head>
<body>
<img id="background" style="position:absolute; left:0px; top:0px;" width="595" height="842" src="page1.png">
<div class="txt" style="position:absolute; left:478px; top:72px;"><span id="f2" style="font-size:12px;vertical-align:baseline;color:rgba(0,0,0,1);">기업 </span><span id="f1" style="font-size:12px;vertical-align:baseline;color:rgba(0,0,0,1);">Note</span></div>
<div class="txt" style="position:absolute; left:492px; top:92px;"><span id="f1" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">2017.10.13</span></div>
<div class="txt" style="position:absolute; left:190px; top:161px;"><span id="f11" style="font-size:20px;vertical-align:baseline;color:rgba(0,160,198,1);">삼성바이오로직스(207940)</span></div>
<div class="txt" style="position:absolute; left:28px; top:192px;"><span id="f2" style="font-size:18px;vertical-align:baseline;color:rgba(0,0,0,1);">매수(유지)</span></div>
<div class="txt" style="position:absolute; left:190px; top:193px;"><span id="f12" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">바이오시밀러는 생산공장도 중요하다!</span></div>
<div class="txt" style="position:absolute; left:28px; top:223px;"><span id="f2" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">목표주가: 440,000원(상향)</span></div>
<div class="txt" style="position:absolute; left:28px; top:252px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">Stock Data</span></div>
<div class="txt" style="position:absolute; left:28px; top:267px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">KOSPI(10/12)</span></div>
<div class="txt" style="position:absolute; left:157px; top:267px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">2,475</span></div>
<div class="txt" style="position:absolute; left:28px; top:278px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주가(10/12)</span></div>
<div class="txt" style="position:absolute; left:149px; top:278px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">377,500</span></div>
<div class="txt" style="position:absolute; left:28px; top:290px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">시가총액(십억원)</span></div>
<div class="txt" style="position:absolute; left:153px; top:290px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">24,977</span></div>
<div class="txt" style="position:absolute; left:28px; top:301px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">발행주식수(백만)</span></div>
<div class="txt" style="position:absolute; left:166px; top:301px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">66</span></div>
<div class="txt" style="position:absolute; left:28px; top:313px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">52주 최고/최저가(원)</span></div>
<div class="txt" style="position:absolute; left:123px; top:313px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">377,500/142,000</span></div>
<div class="txt" style="position:absolute; left:28px; top:324px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">일평균거래대금(6개월, 백만원)</span></div>
<div class="txt" style="position:absolute; left:153px; top:324px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">75,585</span></div>
<div class="txt" style="position:absolute; left:28px; top:335px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">유동주식비율/외국인지분율(%)</span></div>
<div class="txt" style="position:absolute; left:149px; top:335px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">21.8/9.6</span></div>
<div class="txt" style="position:absolute; left:28px; top:347px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주요주주(%) 삼성물산 외 3 인</span></div>
<div class="txt" style="position:absolute; left:160px; top:347px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">75.0</span></div>
<div class="txt" style="position:absolute; left:28px; top:377px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">주가상승률</span></div>
<div class="txt" style="position:absolute; left:28px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">절대주가(%)</span></div>
<div class="txt" style="position:absolute; left:28px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">상대주가(%p)</span></div>
<div class="txt" style="position:absolute; left:92px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">1개월</span></div>
<div class="txt" style="position:absolute; left:95px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">23.8</span></div>
<div class="txt" style="position:absolute; left:95px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">19.2</span></div>
<div class="txt" style="position:absolute; left:125px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">6개월</span></div>
<div class="txt" style="position:absolute; left:124px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">109.7</span></div>
<div class="txt" style="position:absolute; left:128px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">93.5</span></div>
<div class="txt" style="position:absolute; left:154px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">12개월</span></div>
<div class="txt" style="position:absolute; left:168px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:168px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:28px; top:427px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">12MF PER 추이</span></div>
<div class="txt" style="position:absolute; left:29px; top:441px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">800 </span><span id="f8" style="font-size:4px;vertical-align:super;color:rgba(0,0,0,1);">(배)</span></div>
<div class="txt" style="position:absolute; left:29px; top:455px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">700</span></div>
<div class="txt" style="position:absolute; left:29px; top:466px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">600</span></div>
<div class="txt" style="position:absolute; left:29px; top:477px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">500</span></div>
<div class="txt" style="position:absolute; left:73px; top:442px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">12MF PER (좌)</span></div>
<div class="txt" style="position:absolute; left:73px; top:451px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">삼성바이오로직스 주가 (우)</span></div>
<div class="txt" style="position:absolute; left:139px; top:441px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">(천원)</span></div>
<div class="txt" style="position:absolute; left:166px; top:444px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">500</span></div>
<div class="txt" style="position:absolute; left:166px; top:453px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">450</span></div>
<div class="txt" style="position:absolute; left:166px; top:462px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">400</span></div>
<div class="txt" style="position:absolute; left:166px; top:470px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">350</span></div>
<div class="txt" style="position:absolute; left:166px; top:479px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">300</span></div>
<div class="txt" style="position:absolute; left:29px; top:488px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">400</span></div>
<div class="txt" style="position:absolute; left:166px; top:488px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">250</span></div>
<div class="txt" style="position:absolute; left:29px; top:499px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">300</span></div>
<div class="txt" style="position:absolute; left:166px; top:497px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">200</span></div>
<div class="txt" style="position:absolute; left:166px; top:505px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">150</span></div>
<div class="txt" style="position:absolute; left:29px; top:510px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">200</span></div>
<div class="txt" style="position:absolute; left:166px; top:514px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">100</span></div>
<div class="txt" style="position:absolute; left:29px; top:521px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">100</span></div>
<div class="txt" style="position:absolute; left:166px; top:523px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">50</span></div>
<div class="txt" style="position:absolute; left:34px; top:532px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">0</span></div>
<div class="txt" style="position:absolute; left:166px; top:532px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">0</span></div>
<div class="txt" style="position:absolute; left:36px; top:537px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">Nov-14</span></div>
<div class="txt" style="position:absolute; left:76px; top:537px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">Nov-15</span></div>
<div class="txt" style="position:absolute; left:116px; top:537px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">Nov-16</span></div>
<div class="txt" style="position:absolute; left:28px; top:546px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">자료: WISEfn 컨센서스</span></div>
<div class="txt" style="position:absolute; left:189px; top:228px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">바이오시밀러의 생산공장에 대한 중요성 부각</span></div>
<div class="txt" style="position:absolute; left:189px; top:243px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">바이오시밀러 판매승인에 있어 품질뿐 아니라 생산공장에 대한 중요성도 부각되고 있다.</span></div>
<div class="txt" style="position:absolute; left:189px; top:257px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">10월 11일 인도 Biocon과 미국 Mylan이 공동으로 개발한 호중구 감소증 치료제 뉴라스</span></div>
<div class="txt" style="position:absolute; left:189px; top:272px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">타의 바이오시밀러 MYL-1401H는 생산공장 문제로 FDA로부터 판매허가를 보류하는</span></div>
<div class="txt" style="position:absolute; left:189px; top:286px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">CRL(Complete Response Letter)을 통보 받았다. 이 두 업체는 이미 동일한 이유로 유럽</span></div>
<div class="txt" style="position:absolute; left:189px; top:300px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">에서도 허셉틴 바이오시밀러에 대한 승인을 거절당한 바 있다. 한편 삼성바이오로직스는</span></div>
<div class="txt" style="position:absolute; left:189px; top:314px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">10월 12일 2공장의 생산제품에 대해 FDA로부터 제조승인을 획득했다. 이로써 그 동안</span></div>
<div class="txt" style="position:absolute; left:189px; top:328px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">시제품 수탁생산만으로 가동률을 올려왔던 2공장의 내년 가동률 전망치(60%)의 달성 가</span></div>
<div class="txt" style="position:absolute; left:189px; top:343px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">시성도 높아졌다. 앞으로는 고객사들로부터 시제품 뿐 아닌 미국에 실제 판매 가능한 제</span></div>
<div class="txt" style="position:absolute; left:189px; top:357px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">품들에 대한 생산주문도 받을 수 있기 때문이다.</span></div>
<div class="txt" style="position:absolute; left:189px; top:384px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">3공장 가동률도 문제없다</span></div>
<div class="txt" style="position:absolute; left:189px; top:399px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">이번 Mylan과 Biocon의 생산공장 이슈와 삼성바이오로직스 2공장의 FDA승인이 맞물리</span></div>
<div class="txt" style="position:absolute; left:189px; top:414px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">면서 삼성바이오로직스의 설비에 대한 고객사들의 인식과 수요가 한층 증대될 것이다. 1</span></div>
<div class="txt" style="position:absolute; left:189px; top:428px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">공장(연간 생산능력 3만 리터)은 승인을 얻는데 25개월이 걸린 반면 2공장(연간 생산능력</span></div>
<div class="txt" style="position:absolute; left:189px; top:442px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">15만 리터)은 생산캐파가 1공장보다 더 큼에도 6개월을 단축시켰다. 삼성바이오로직스의</span></div>
<div class="txt" style="position:absolute; left:189px; top:456px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">생선설비 우수성이 입증됨에 따라 2019년 말 가동 예정인 3공장의 신규고객 유치 가능성</span></div>
<div class="txt" style="position:absolute; left:189px; top:470px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">도 높아졌으며 3공장의 풀가동 달성시기도 기존 우리의 전망치 2023년보다 1년 빨라질</span></div>
<div class="txt" style="position:absolute; left:189px; top:485px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">것으로 예상한다.</span></div>
<div class="txt" style="position:absolute; left:189px; top:512px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">3공장 가동률 전망치 올리며 목표주가 44만원으로 10% 상향</span></div>
<div class="txt" style="position:absolute; left:189px; top:527px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">삼성바이오로직스에 대해 매수 의견을 유지하고 목표주가를 기존 40만원에서 44만원으로</span></div>
<div class="txt" style="position:absolute; left:189px; top:541px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">10% 상향한다. 목표주가 상향의 주요 근거는 3공장의 가동률 전망치 상향에 따른 FCF(잉</span></div>
<div class="txt" style="position:absolute; left:189px; top:556px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">여현금흐름) 개선에 기인한다. 그동안 삼성바이오로직스의 3공장에 대해 신규 고객사 유</span></div>
<div class="txt" style="position:absolute; left:189px; top:570px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">치 가능성에 대한 우려가 존재해왔다. 그러나 바이오의약품과 바이오시밀러의 수요가 지</span></div>
<div class="txt" style="position:absolute; left:189px; top:584px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">속적으로 증가함과 동시에 생산공장에 대한 중요성이 부각되면서 삼성바이오로직스에 생</span></div>
<div class="txt" style="position:absolute; left:189px; top:598px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">산을 수탁하는 고객사도 더욱 늘어날 전망이다. 삼성바이오로직스는 2분기 마지막 영업적</span></div>
<div class="txt" style="position:absolute; left:189px; top:612px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">자를 뒤로 하고 3분기부터는 흑자기조를 이어가는 한편 바이오에피스는 세계시장에 신제</span></div>
<div class="txt" style="position:absolute; left:189px; top:627px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">품을 지속적으로 출시해 나갈 전망이다. CMO 세계 1위 등극이 예정돼 있고 바이오시밀러</span></div>
<div class="txt" style="position:absolute; left:189px; top:641px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">를 넘어 신약개발업체로 변모해 나갈 삼성바이오로직스에 대해 긴 호흡에서 매수를 권고</span></div>
<div class="txt" style="position:absolute; left:189px; top:655px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">한다.</span></div>
<div class="txt" style="position:absolute; left:29px; top:721px;"><span id="f5" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">진홍국</span></div>
<div class="txt" style="position:absolute; left:29px; top:733px;"><span id="f3" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">hg.jin@truefriend.com</span></div>
<div class="txt" style="position:absolute; left:29px; top:751px;"><span id="f5" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">정은영</span></div>
<div class="txt" style="position:absolute; left:29px; top:763px;"><span id="f3" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">eunice.jung@truefriend.com</span></div>
<div class="txt" style="position:absolute; left:228px; top:694px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">매출액 영업이익 순이익</span></div>
<div class="txt" style="position:absolute; left:336px; top:694px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">EPS 증감률 EBITDA PER </span><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">EV/EBITDA </span><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">PBR ROE DY</span></div>
<div class="txt" style="position:absolute; left:223px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(십억원) (십억원) (십억원)</span></div>
<div class="txt" style="position:absolute; left:338px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(원)</span></div>
<div class="txt" style="position:absolute; left:367px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(%) (십억원)</span></div>
<div class="txt" style="position:absolute; left:428px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(x)</span></div>
<div class="txt" style="position:absolute; left:457px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(x) (x) (%) (%)</span></div>
<div class="txt" style="position:absolute; left:189px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2015A</span></div>
<div class="txt" style="position:absolute; left:240px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">91</span></div>
<div class="txt" style="position:absolute; left:265px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(204) 1,905 19,414</span></div>
<div class="txt" style="position:absolute; left:368px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM (162) NM</span></div>
<div class="txt" style="position:absolute; left:455px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM NM 68.7</span></div>
<div class="txt" style="position:absolute; left:534px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2016A</span></div>
<div class="txt" style="position:absolute; left:236px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">295</span></div>
<div class="txt" style="position:absolute; left:269px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(30)</span></div>
<div class="txt" style="position:absolute; left:300px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(177) (1,558)</span></div>
<div class="txt" style="position:absolute; left:368px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM</span></div>
<div class="txt" style="position:absolute; left:402px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">30 NM 320.6 4.9 (5.2)</span></div>
<div class="txt" style="position:absolute; left:534px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2017F</span></div>
<div class="txt" style="position:absolute; left:236px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">421</span></div>
<div class="txt" style="position:absolute; left:277px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">9</span></div>
<div class="txt" style="position:absolute; left:300px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(126) (1,904)</span></div>
<div class="txt" style="position:absolute; left:368px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM</span></div>
<div class="txt" style="position:absolute; left:402px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">71 NM 351.1 7.0 (3.3)</span></div>
<div class="txt" style="position:absolute; left:534px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2018F</span></div>
<div class="txt" style="position:absolute; left:236px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">578</span></div>
<div class="txt" style="position:absolute; left:270px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">105</span></div>
<div class="txt" style="position:absolute; left:304px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">528 1,423</span></div>
<div class="txt" style="position:absolute; left:368px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM</span></div>
<div class="txt" style="position:absolute; left:399px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">184 47.3 134.2 6.3 14.0</span></div>
<div class="txt" style="position:absolute; left:534px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2019F</span></div>
<div class="txt" style="position:absolute; left:236px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">956</span></div>
<div class="txt" style="position:absolute; left:270px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">334</span></div>
<div class="txt" style="position:absolute; left:304px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">292 4,407 209.7</span></div>
<div class="txt" style="position:absolute; left:399px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">439 85.7 55.6 5.8 7.0</span></div>
<div class="txt" style="position:absolute; left:534px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
</body>
</html>
